Filing Details
- Accession Number:
- 0001140361-18-009201
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-20 20:40:56
- Reporting Period:
- 2018-02-15
- Accepted Time:
- 2018-02-20 20:40:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1221590 | Jacques Jean Bienaime | C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-15 | 10,000 | $38.59 | 236,494 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-15 | 10,000 | $84.63 | 226,494 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy Common Stock) | Disposition | 2018-02-15 | 10,000 | $0.00 | 10,000 | $38.59 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 172,500 | 2008-11-22 | 2018-05-21 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 182,201 | Indirect | Shares held by Jean-Jacques Bienaime Family Trust |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
- The price in column 4 is the weighted average price. The price actually received ranged from $84.095 to $84.98. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- Amount of securities beneficially owned has been updated from the reporting person's prior report to include 600 shares reported in the Form 4 Amendment filed with the S.E.C. on 01/02/2018.
- Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 600 shares reported in the Form 4 Amendment filed with the S.E.C. on 01/02/2018.
- Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
Billionaire Hedge Funds
